# A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers

> **NCT00951873** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 38 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A
- Haemophilia B
- Healthy

## Interventions

- **DRUG:** activated recombinant human factor VII, long acting
- **DRUG:** placebo
- **DRUG:** activated recombinant human factor VII, long acting

## Key facts

- **NCT ID:** NCT00951873
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2016-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00951873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00951873, "A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00951873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*